.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Heart Failure

Heart Failure Clinical and Economic Burden

An in-depth discussion on the clinical and economic burden of treatment for patients with heart failure, with special consideration to progressive disease.

The Progressive Nature of Heart Failure

An expert in the management of heart failure provides an overview of the progressive nature of the disease, with special consideration to biomarker monitorization.

Dr Adriaan Voors Explains Potential Decongestive Benefits of Empagliflozin

December 2nd 2021, 2:00pm

Video

Adriaan Voors, MD, discusses possible mechanisms of action of empagliflozin that produce such beneficial results among patients with heart failure, in an interview about the EMPULSE trial prior to this year’s American Heart Association Scientific Sessions.

SGLT2 Inhibitors Show Success Against HFpEF in New UK Study

December 1st 2021, 12:05am

Article

This new investigation into the use of sodium-glucose co-transporter 2 (SGLT2) inhibitors for heart failure shows significant benefit in persons with heart failure with preserved ejection fraction (HFpEF).

Experts Urge Caution on Aspirin Use Among Persons With HF Risk

November 23rd 2021, 12:05am

Article

A new analysis of data from the HOMAGE study addresses previous mixed results on the use of aspirin among patients who may be at risk of heart failure (HF).

Sacubitril/Valsartan Treatment for HFpEF Shown to Reduce NT-proBNP Levels

November 18th 2021, 1:00pm

Article

Wanting more data on the benefits of sacubitril/valsartan vs renin angiotensin system inhibitor background therapy, investigators conducted a large randomized study among persons with heart failure with preserved ejection fraction (HFpEF).

Dr Adriaan Voors Discusses Initiating SGLT2 Inhibitors During Hospitalization

November 16th 2021, 12:00pm

Video

Adriaan Voors, MD, professor of cardiology and director of the Heart Failure Clinic, University Medical Center Groningen, the Netherlands, addresses the lack of prescribing for sodium-glucose co-transporter 2 (SGLT2) inhibitors during hospitalization for acute heart failure by highlighting their benefits and that they are part of guideline-directed treatment.

Mortality Increase Seen in Patients With Heart Failure, Hypercapnia

November 10th 2021, 2:30pm

Article

Outcomes of in-hospital mortality, 7-day mortality, and emergency department length of stay were investigated among a cohort of patients with acute heart failure and hypercapnia, or excessive levels of CO2 in the blood.

Early Use of Sacubitril/Valsartan Linked to Improved Cardiac Function Post AMI

November 2nd 2021, 9:00pm

Article

Individuals with a history of acute myocardial infarction (AMI), or heart attack, may benefit on several fronts following early administration of the neprilysin inhibitor/angiotensin receptor blocker sacubitril/valsartan.

Social Vulnerability Linked to Premature Cardiovascular Deaths

October 29th 2021, 1:45pm

Article

The counties in the United States with more social vulnerabilities had higher premature mortality related to cardiovascular diseases, such as heart disease, stroke, high blood pressure, and heart failure.

Obesity Shown to Adversely Influence Heart Health Prior to Symptom Onset

October 27th 2021, 8:45pm

Article

For 3 categories of evaluation, elevated cardiac troponin I levels most influenced the development of myocardial injury among persons at higher lifetime weight totals.

Older Adults Should Not Take Aspirin to Prevent Heart Disease, USPSTF Recommends

October 13th 2021, 7:46pm

Article

The task force determined that potential harms of adults aged 60 and older using aspirin for prevention outweighed the benefits.